📊 CYCN Key Takeaways
Is Cyclerion Therapeutics, Inc. (CYCN) a Good Investment?
Cyclerion is a pre-commercial pharmaceutical company with zero revenue, significant operating losses of $3.2M, and negative free cash flow of $1.2M, indicating failed or stalled product development. With only $2.8M in cash and a burn rate of ~$1.2M annually, the company has approximately 2-3 years of runway before requiring dilutive financing. The absence of any commercial revenue generation in a pharmaceutical context suggests either failed clinical trials or products stuck in development.
Cyclerion Therapeutics shows very weak fundamentals, with minimal revenue, deeply negative operating and net margins, and negative free cash flow that indicates the business is not self-sustaining. While the balance sheet is currently supported by strong liquidity and no meaningful leverage, the small cash base relative to ongoing losses creates substantial funding and dilution risk unless operating performance improves materially.
Cyclerion Therapeutics, Inc. Key Strengths (CYCN)
- No long-term debt (0.00x debt-to-equity ratio)
- Current ratio of 1.80x indicates adequate short-term liquidity
- Cash reserves of $2.8M provide near-term operational cushion
- Strong near-term liquidity with current and quick ratios of 5.78x
- No meaningful debt burden, reducing balance-sheet stress
- Positive stockholders' equity of $9.54M provides some financial cushion
CYCN Stock Risks: Cyclerion Therapeutics, Inc. Investment Risks
- Zero revenue indicates no commercialized products or failed market entry
- Annual cash burn of $1.2M with only 2-3 years of runway remaining
- Negative ROE (-46.8%) and ROA (-37.4%) reflect fundamental unprofitability
- No insider activity in past 90 days suggests low confidence from management
- Limited cash runway necessitates additional capital raises, likely dilutive to shareholders
- Extremely weak profitability, with operating margin of -394.2% and net margin of -260.2%
- Negative operating cash flow and free cash flow indicate continuing cash burn
- Low revenue base of $1.05M suggests limited commercial scale and poor growth quality
Key Metrics to Watch
- Cash burn rate and months of runway remaining
- Clinical trial progress and regulatory milestone achievements
- Timing and success of product commercialization events
- Capital raise activities and dilution impact
- Operating expense trends relative to pipeline advancement
- Quarterly operating cash burn relative to cash and equivalents
- Revenue growth and improvement in operating loss margin
Cyclerion Therapeutics, Inc. (CYCN) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Cyclerion Therapeutics, Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
CYCN Profit Margin, ROE & Profitability Analysis
CYCN vs Healthcare Sector: How Cyclerion Therapeutics, Inc. Compares
How Cyclerion Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Cyclerion Therapeutics, Inc. Stock Overvalued? CYCN Valuation Analysis 2026
Based on fundamental analysis, Cyclerion Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Cyclerion Therapeutics, Inc. Balance Sheet: CYCN Debt, Cash & Liquidity
CYCN Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Cyclerion Therapeutics, Inc.'s revenue has declined by 47% over the 5-year period, indicating business contraction. The most recent EPS of $-1.21 indicates the company is currently unprofitable.
CYCN Revenue Growth, EPS Growth & YoY Performance
CYCN Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | N/A | -$1.4M | $-0.56 |
| Q3 2025 | $194.0K | -$324.0K | $-0.29 |
| Q2 2025 | N/A | -$324.0K | $-0.11 |
| Q1 2025 | N/A | -$1.4M | $-0.56 |
| Q3 2024 | N/A | -$723.0K | $-0.29 |
| Q3 2023 | N/A | -$3.6M | $-1.55 |
| Q2 2023 | N/A | -$4.2M | $-1.83 |
| Q1 2023 | N/A | -$7.0M | $-0.16 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Cyclerion Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
CYCN SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Cyclerion Therapeutics, Inc. (CIK: 0001755237)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CYCN
What is the AI rating for CYCN?
Cyclerion Therapeutics, Inc. (CYCN) has a Combined AI Grade of D from Claude (D) and ChatGPT (D) with 88% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are CYCN's key strengths?
Claude: No long-term debt (0.00x debt-to-equity ratio). Current ratio of 1.80x indicates adequate short-term liquidity. ChatGPT: Strong near-term liquidity with current and quick ratios of 5.78x. No meaningful debt burden, reducing balance-sheet stress.
What are the risks of investing in CYCN?
Claude: Zero revenue indicates no commercialized products or failed market entry. Annual cash burn of $1.2M with only 2-3 years of runway remaining. ChatGPT: Extremely weak profitability, with operating margin of -394.2% and net margin of -260.2%. Negative operating cash flow and free cash flow indicate continuing cash burn.
What is CYCN's revenue and growth?
Cyclerion Therapeutics, Inc. reported revenue of $0.0.
Does CYCN pay dividends?
Cyclerion Therapeutics, Inc. does not currently pay dividends.
Where can I find CYCN SEC filings?
Official SEC filings for Cyclerion Therapeutics, Inc. (CIK: 0001755237) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CYCN's EPS?
Cyclerion Therapeutics, Inc. has a diluted EPS of $-0.76.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is CYCN's fundamental grade?
Based on our AI fundamental analysis in June 2026, Cyclerion Therapeutics, Inc. has a D grade with 88% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is CYCN stock overvalued or undervalued?
Valuation metrics for CYCN: ROE of -46.8% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is CYCN's AI grade for 2026?
Our dual AI analysis gives Cyclerion Therapeutics, Inc. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is CYCN's free cash flow?
Cyclerion Therapeutics, Inc.'s operating cash flow is $-1.2M, with capital expenditures of $66.0K.
How does CYCN compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -46.8% (avg: 15%), current ratio 1.80 (avg: 2).